D-0609-2017 Class III Terminated
FDA drug recall D-0609-2017 was initiated by Pfizer Inc on Mar 7, 2017 and is designated Class III. Reason for recall: Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius. The recall status is terminated (terminated May 31, 2019). Affected quantity: 9,666 units.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 29, 2017
- Initiation Date
- Mar 7, 2017
- Termination Date
- May 31, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 9,666 units
Product description
Quillivant XR (methylphenidate HCl) for extended-release oral suspension, 900 mg/180 mL (25mg/5mL), Rx Only, Distributed by: NextWave Pharmaceuticals, Inc. A subsidiary of Pfizer Inc, New York, NY 10017 Manufactured by: Tris Pharma, Inc., Monmouth Junction, NJ 08852 (NDC 24478-190-30).
Reason for recall
Failed Dissolution Specifications: Dissolution at 8 hour was out of specification at 12 month at 25 degree Celsius.
Distribution pattern
Nationwide within US
Code information
Lot #: 03216025A, Exp.01/18.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0609-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026